Q3 Financial Surge: Recent chatter on X about Invivyd, Inc. (IVVD) has centered on the company’s impressive third-quarter 2025 financial results. Posts highlight a 41% year-over-year revenue increase to $13.1 million, sparking interest among investors. Many are discussing the potential for sustained growth as the company advances its biopharmaceutical initiatives.
FDA Approval Buzz: Another hot topic on X is the FDA’s clearance of the Investigational New Drug application for VYD2311, with pivotal trials expected by year-end 2025. Users are excited about the implications for Invivyd’s pipeline in combating viral diseases. The recent $57.5 million public offering to support these trials is also fueling optimistic conversations.
Analyst Optimism: Discussions also note a significant analyst upgrade, with a doubled price target to $10 from $5 by a major firm, as reported on X. Several posts reflect enthusiasm about the stock’s potential for substantial returns, driven by strong margins and a robust R&D pipeline. The momentum appears to be building as more investors tune in.
Note: This discussion summary was generated from an AI condensation of post data.
Invivyd, Inc. Insider Trading Activity
Invivyd, Inc. insiders have traded $IVVD stock on the open market 10 times in the past 6 months. Of those trades, 0 have been purchases and 10 have been sales.
Here’s a breakdown of recent trading of $IVVD stock by insiders over the last 6 months:
- JILL ANDERSEN (Chief Legal Officer, Secretary) has made 0 purchases and 2 sales selling 82,754 shares for an estimated $49,676.
- WILLIAM E. DUKE (Chief Financial Officer) has made 0 purchases and 2 sales selling 49,656 shares for an estimated $29,808.
- JULIE GREEN (Chief Human Resources Officer) has made 0 purchases and 2 sales selling 49,656 shares for an estimated $29,808.
- TIMOTHY EDWARD LEE (Chief Commercial Officer) has made 0 purchases and 2 sales selling 49,656 shares for an estimated $29,808.
- ROBERT D. III ALLEN (Chief Scientific Officer) has made 0 purchases and 2 sales selling 45,932 shares for an estimated $27,572.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Invivyd, Inc. Hedge Fund Activity
We have seen 29 institutional investors add shares of Invivyd, Inc. stock to their portfolio, and 58 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VANGUARD GROUP INC added 1,834,970 shares (+46.7%) to their portfolio in Q3 2025, for an estimated $2,018,467
- MILLENNIUM MANAGEMENT LLC added 1,249,093 shares (+inf%) to their portfolio in Q2 2025, for an estimated $893,101
- DEEP TRACK CAPITAL, LP removed 1,136,274 shares (-11.7%) from their portfolio in Q2 2025, for an estimated $812,435
- BLACKROCK, INC. removed 967,676 shares (-57.4%) from their portfolio in Q3 2025, for an estimated $1,064,443
- ORBIMED ADVISORS LLC removed 933,500 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $667,452
- UBS GROUP AG removed 853,996 shares (-86.4%) from their portfolio in Q3 2025, for an estimated $939,395
- MAVERICK CAPITAL LTD removed 729,454 shares (-6.7%) from their portfolio in Q2 2025, for an estimated $521,559
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Invivyd, Inc. Analyst Ratings
Wall Street analysts have issued reports on $IVVD in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 11/03/2025
- Cantor Fitzgerald issued a "Overweight" rating on 10/06/2025
- D. Boral Capital issued a "Buy" rating on 08/19/2025
To track analyst ratings and price targets for Invivyd, Inc., check out Quiver Quantitative's $IVVD forecast page.
Invivyd, Inc. Price Targets
Multiple analysts have issued price targets for $IVVD recently. We have seen 4 analysts offer price targets for $IVVD in the last 6 months, with a median target of $7.5.
Here are some recent targets:
- Patrick R. Trucchio from HC Wainwright & Co. set a target price of $10.0 on 11/03/2025
- Josh Schimmer from Cantor Fitzgerald set a target price of $10.0 on 10/06/2025
- Jason Kolbert from D. Boral Capital set a target price of $2.0 on 10/06/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
